Bicyclic amido compounds with antiprotozoal activity (Publications)
tested for their activities against the causative organisms of East African trypanosomiasis and malaria tropica. The acylation induced in general loss of antiprotozoal activity, but a single compound showed
Synthesis of antimalarial 1,2,4-trioxanes via photooxygenation of a chiral allylic alcohol (Publications)
series of monocyclic and spirobicyclic 1,2,4-trioxanes (5, 6). Two products show significant anti-Malaria activity against Plasmodium falciparum when compared with chloroquine
Diaryl ureas as an antiprotozoal chemotype (Publications)
kinetic aq. solubilities were /=10. One N,N'-diarylurea had demonstrable activity in mouse models of malaria and toxoplasmosis.
SARs of the antiprotozoal action of 6,7-diaryl-bicyclo[2.2.2]octan-2-ols (Publications)
tested for their activity against the causative organisms of East African sleeping sickness and malaria tropica. Structure activity relationships are discussed
SARs of the antiprotozoal action of 6,7-diaryl-bicyclo[2.2.2]octan-2-ols (Publications)
tested for their activity against the causative organisms of East African sleeping sickness and malaria tropica. Structure activity relationships are discussed
Diaryl ureas as an antiprotozoal chemotype (Publications)
kinetic aq. solubilities were /=10. One N,N'-diarylurea had demonstrable activity in mouse models of malaria and toxoplasmosis.
A paradigm for Africa-centric vaccine development in Equatorial Guinea (Publications)
The Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development
Synthesis of szentiamide, a depsipeptide from entomopathogenic <em>Xenorhabdus szentirmaii</em> with activity against <em>Plasmodium falciparum</em> (Publications)
on of a notable activity against insect cells and Plasmodium falciparum, the causative agent of malaria
Synthesis of szentiamide, a depsipeptide from entomopathogenic <em>Xenorhabdus szentirmaii</em> with activity against <em>Plasmodium falciparum</em> (Publications)
on of a notable activity against insect cells and Plasmodium falciparum, the causative agent of malaria
A paradigm for Africa-centric vaccine development in Equatorial Guinea (Publications)
The Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development